164 related articles for article (PubMed ID: 24833256)
1. Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.
De Waele JJ; Tellado JM; Weiss G; Alder J; Kruesmann F; Arvis P; Hussain T; Solomkin JS
Surg Infect (Larchmt); 2014 Oct; 15(5):567-75. PubMed ID: 24833256
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Gyssens IC; Dryden M; Kujath P; Nathwani D; Schaper N; Hampel B; Reimnitz P; Alder J; Arvis P
J Antimicrob Chemother; 2011 Nov; 66(11):2632-42. PubMed ID: 21896561
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
[TBL] [Abstract][Full Text] [Related]
5. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Schaper NC; Dryden M; Kujath P; Nathwani D; Arvis P; Reimnitz P; Alder J; Gyssens IC
Infection; 2013 Feb; 41(1):175-86. PubMed ID: 23180507
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Vick-Fragoso R; Hernández-Oliva G; Cruz-Alcázar J; Amábile-Cuevas CF; Arvis P; Reimnitz P; Bogner JR;
Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
Höffken G; Barth J; Rubinstein E; Beckmann H;
Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
Weiss G; Reimnitz P; Hampel B; Muehlhofer E; Lippert H;
J Chemother; 2009 Apr; 21(2):170-80. PubMed ID: 19423470
[TBL] [Abstract][Full Text] [Related]
12. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Lode H; Grossman C; Choudhri S; Haverstock D; McGivern J; Herman-Gnjidic Z; Church D
Respir Med; 2003 Oct; 97(10):1134-42. PubMed ID: 14561021
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
Ross JD; Cronjé HS; Paszkowski T; Rakoczi I; Vildaite D; Kureishi A; Alefelder M; Arvis P; Reimnitz P;
Sex Transm Infect; 2006 Dec; 82(6):446-51. PubMed ID: 16723364
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials.
Andriole VT; Haverstock DC; Choudhri SH
Drug Saf; 2005; 28(5):443-52. PubMed ID: 15853445
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal Vancomycin Plus Either Oral Moxifloxacin or Intraperitoneal Ceftazidime for the Treatment of Peritoneal Dialysis-Related Peritonitis: A Randomized Controlled Pilot Study.
Xu R; Yang Z; Qu Z; Wang H; Tian X; Johnson DW; Dong J
Am J Kidney Dis; 2017 Jul; 70(1):30-37. PubMed ID: 28027794
[TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.
De Waele JJ; Tellado JM; Alder J; Reimnitz P; Jensen M; Hampel B; Arvis P
Int J Antimicrob Agents; 2013 Jan; 41(1):57-64. PubMed ID: 23153963
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis.
Ferguson BJ; Guzzetta RV; Spector SL; Hadley JA
Otolaryngol Head Neck Surg; 2004 Sep; 131(3):207-14. PubMed ID: 15365537
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
Goldstein EJ; Solomkin JS; Citron DM; Alder JD
Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin safety: an analysis of 14 years of clinical data.
Tulkens PM; Arvis P; Kruesmann F
Drugs R D; 2012 Jun; 12(2):71-100. PubMed ID: 22715866
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
